October 2, 2014 | The cancer and immune-inflammatory treatments developer VBL Therapeutics raised $40 million at a company value of $120 million in a revived NASDAQ IPO. Just this August, the company had raised $65 million at a company value of $222 million, but after a principle US investor couldn’t come through with the money promised, the company was forced to cancel its offering and delist. In this, the latest offering, the company sold over 6 million shares at $6 per share, but by the end of the day the share price had fallen to $5.85. Deutsche Bank Services was the book-running manager for the IPO, together with co-managers JMP Securities and Oppenheimer. VBL Therapeutics was founded in 2000 and is based in Tel Aviv.